Premium
Cleavage and polyadenylation specificity factor (CPSF)‐derived peptides can induce HLA‐A2‐restricted and tumor‐specific CTLs in the majority of gastrointestinal cancer patients
Author(s) -
Maeda Yoshiaki,
Ito Masaaki,
Harashima Nanae,
Nakatsura Tetsuya,
Hida Naoya,
Imai Nobue,
Sato Yuuji,
Shichijo Shigeki,
Todo Satoru,
Itoh Kyogo
Publication year - 2002
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.10377
Subject(s) - ctl* , cleavage and polyadenylation specificity factor , biology , polyadenylation , antigen , immunology , human leukocyte antigen , cancer research , cancer , immunotherapy , cytotoxic t cell , immune system , gene , messenger rna , genetics , cd8 , in vitro
Abstract To identify CTL‐directed antigens in gastrointestinal cancer, we have investigated antigens recognized by the HLA‐A2‐restricted CTL line established from T cells infiltrating into colon cancer and report herein cleavage and polyadenylation specificity factor (CPSF) as a potent antigen holding peptides capable of inducing CTLs. Five peptides at amino acid positions 250–258, 392–400, 534–542, 1296–1304 and 1359–1368 of CPSF, which were recognized by the CTL line, were found to have the ability to induce HLA‐A2‐restricted and tumor‐specific CTLs in peripheral blood mononuclear cells of the majority (69%, 11/16) of gastrointestinal cancer patients with different HLA‐A2 subtypes. Thus, these peptides might be appropriate molecules for use in the peptide‐based specific immunotherapy of HLA‐A2 + patients with gastrointestinal cancers. © 2002 Wiley‐Liss, Inc.